These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33681331)

  • 21. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis.
    Visser M; Walsh K; King V; Sture G; Caneva L
    BMC Vet Res; 2022 Mar; 18(1):103. PubMed ID: 35300697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
    Souza CP; Rosychuk RAW; Contreras ET; Schissler JR; Simpson AC
    Vet Dermatol; 2018 Dec; 29(6):489-e164. PubMed ID: 30141223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botanical oleander extract and oleandrin have superior effects on innate immune functions pertaining to dermal allergic reactions in canine cells when compared to oclacitinib.
    Fossum TW; Jensen GS; Newman RA; Matos JR
    Am J Vet Res; 2024 Oct; ():1-7. PubMed ID: 39362280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of oclacitinib as antipruritic drug during sarcoptic mange infestation treatment.
    Cornegliani L; Guidi E; Vercelli A
    Vet Dermatol; 2020 Dec; 31(6):505. PubMed ID: 33226173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
    Panteri A; Strehlau G; Helbig R; Prost C; Doucette K
    Vet Dermatol; 2016 Feb; 27(1):22-e7. PubMed ID: 26660461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
    Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
    Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
    Banovic F; Tarigo J; Gordon H; Barber JP; Gogal RM
    Vet Dermatol; 2019 Feb; 30(1):17-e6. PubMed ID: 30417482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dog Owners' Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey.
    Wright A; Hillier A; Lambert J; Mwacalimba K; Lloyd N; Kagiwada T; Hashiguchi Y; Hours C; Riley D; Enstone A; Wyn R
    Animals (Basel); 2024 Mar; 14(6):. PubMed ID: 38540050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis.
    Gonzales AJ; Humphrey WR; Messamore JE; Fleck TJ; Fici GJ; Shelly JA; Teel JF; Bammert GF; Dunham SA; Fuller TE; McCall RB
    Vet Dermatol; 2013 Feb; 24(1):48-53.e11-2. PubMed ID: 23331679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA).
    Olivry T; DeBoer DJ; Favrot C; Jackson HA; Mueller RS; Nuttall T; Prélaud P;
    BMC Vet Res; 2015 Aug; 11():210. PubMed ID: 26276051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of oclacitinib in the management of ischaemic dermatopathy in four dogs.
    Levy BJ; Linder KE; Olivry T
    Vet Dermatol; 2019 Jun; 30(3):201-e63. PubMed ID: 31006925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity and specificity of a shortened elimination diet protocol for the diagnosis of food-induced atopic dermatitis (FIAD).
    Fischer N; Spielhofer L; Martini F; Rostaher A; Favrot C
    Vet Dermatol; 2021 Jun; 32(3):247-e65. PubMed ID: 33565651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib.
    Haugh IM; Watson IT; Alan Menter M
    Proc (Bayl Univ Med Cent); 2018 Oct; 31(4):524-525. PubMed ID: 30949000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs.
    Bruet V; Mosca M; Briand A; Bourdeau P; Pin D; Cochet-Faivre N; Cadiergues MC
    Vet Sci; 2022 Mar; 9(4):. PubMed ID: 35448647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Cytopoint in the Allergic Dog.
    Gober M; Hillier A; Vasquez-Hidalgo MA; Amodie D; Mellencamp MA
    Front Vet Sci; 2022; 9():909776. PubMed ID: 35928119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
    Barrett LE; Gardner HL; Barber LG; Sadowski A; London CA
    BMC Vet Res; 2019 Aug; 15(1):291. PubMed ID: 31409327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of low-level laser therapy on localized canine atopic dermatitis severity score and localized pruritic visual analog score in pedal pruritus due to canine atopic dermatitis.
    Stich AN; Rosenkrantz WS; Griffin CE
    Vet Dermatol; 2014 Oct; 25(5):464-e74. PubMed ID: 24909192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.
    Gonzales AJ; Bowman JW; Fici GJ; Zhang M; Mann DW; Mitton-Fry M
    J Vet Pharmacol Ther; 2014 Aug; 37(4):317-24. PubMed ID: 24495176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oclacitinib 10 years later: lessons learned and directions for the future.
    Marsella R; Doerr K; Gonzales A; Rosenkrantz W; Schissler J; White A
    J Am Vet Med Assoc; 2023 Jun; 261(S1):S36-S47. PubMed ID: 36944222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human interferon-α14 for the treatment of canine allergic pruritic disease in eight dogs.
    Beirão BCB; Taraciuk AC; Trentin C; Ingberman M; Caron LF; McKenzie C; Stimson WH
    Vet Rec Open; 2021 Dec; 8(1):e6. PubMed ID: 33981440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.